For The Better

Analysts are eager to hear from the company on demand trends for AI and data center hardware.

It’s time to reward yourself with companies that treat their shareholders with steady and growing payouts.

Social media could be turned on its head.

Wall Street is surprised to watch this company come to life after it was left for dead.

Down 35% in 2024, Tesla stock is heading in the wrong direction, and news of more price cuts isn’t helping.

Jabil reported a big GAAP profit on Friday, but that’s only the start of the story.

The Boeing supplier continues to face financial challenges and quality control questions.

A Wall Street analyst sees defense profit margin improving and Pratt & Whitney overcoming the engine inspections issue.

Novo Nordisk might be best known for Ozempic, but the company just received positive news from the FDA for an entirely different drug.

This could be a buy-the-dip opportunity for long-term investors.

Nvidia has a bright future despite its already stellar performance.

Don’t jump on the bandwaggon too quickly.

A couple of years ago, Pfizer’s shares may have seemed like a sure thing. That may not be the case anymore.

The company’s valuation may be high but that doesn’t mean Eli Lilly is anywhere near its peak.

Rithm offers a big dividend, but there’s more to the business that investors should be aware of.

The furnishings retailer had some good news for investors on its quarterly update.

Oil majors continue to look like a good value even as the price of oil hovers around $80 a barrel.

After coming back to reality, On Holding might be worth a look.

Rivian’s new R2 and R3 both look great, but Rivian needs to build them before it can sell them (or profit from them).

Most retirees will notice a financial gap between their Social Security payout and their monthly expenses.